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Interventions for the management of malignant pleural
effusions: an updated network meta-analysis
To the Editor:
Malignant pleural effusion (MPE) is a commonly encountered clinical problem, causing disabling
breathlessness and affecting up to 15% of all patients with cancer [1]. Wider availability of indwelling
pleural catheters (IPCs) and recent development of different IPC drainage strategies has expanded the range
of treatment approaches. Incorporating results from several high quality, large randomised controlled trials
(RCTs), we have updated the 2016 Cochrane review [2] to determine the efficacy of different interventions
for MPE. We performed a multiple interventions systematic review, pairwise meta-analyses and network
meta-analyses (NMA) with the primary outcome of pleurodesis success. Secondary outcomes included
adverse events, breathlessness, quality of life, cost, mortality, survival, duration of inpatient stay and
patient acceptability [3]. Here, we summarise key findings of the review to increase accessibility of the
“take home” messages among the wider respiratory community.
Full details of the methods are reported in the Cochrane publication [3]. Through database searches, review of
references of relevant publications and trials registry screening, we identified RCTs of intrapleural interventions
for adults with symptomatic MPE. Two reviewers independently extracted data from eligible RCTs and
completed the Cochrane risk of bias assessment. Where two or more studies provided direct evidence on a
treatment comparison, we performed pairwise meta-analysis using a random-effects model. For studies deemed
to be jointly randomisable (whereby it is assumed that patients who fulfil inclusion criteria are equally likely to
be randomised to any of the interventions), we performed a multiple interventions NMA of primary outcome
data and secondary outcomes with sufficient data using a Bayesian random-effects model.
NMA of interventions in a connected network provided odds ratio estimates representing all possible
pairwise comparisons, including those that had not been directly compared in RCTs. Estimates of the rank
of each intervention in the network, with a 95% credible interval (Cr-I) were generated. We performed
sensitivity analyses for our primary outcome by excluding trials with certain characteristics, such as those
at high risk of bias, to assess whether heterogeneity was reduced. We assessed the certainty of evidence
using GRADE and presented summary of findings tables for the most commonly studied interventions.
1415 records were identified, from which 156 full texts were assessed for eligibility. 18 studies met
inclusion criteria, providing data from 2079 additional participants. These were combined with the 62
studies included in the 2016 review, giving a total of 80 studies of 5507 participants.
The primary NMA on pleurodesis failure included 55 studies (3758 participants) of 21 interventions, with five
additional interventions included since the last iteration of this review. A number of interventions were not felt
to be jointly randomisable (such as specific surgical techniques or tumour dependent intra-pleural
chemotherapy) and hence not included in the network. Talc slurry was the most studied agent (907 participants
randomised across 19 studies) and therefore used as the comparator in our summary of findings (table 1).
Our primary NMA evaluating pleurodesis failure provided weak evidence that talc poudrage may have
fewer pleurodesis failures than talc slurry via a standard chest drain (OR 0.50 (95% Cr-I 0.21–1.02)).
However, pairwise meta-analysis of four statistically homogenous trials indicated comparable pleurodesis
efficacy (OR 0.81 (95% CI 0.61–1.08)), further supported by a sensitivity NMA restricted to studies at low
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risk of bias (OR 0.78 (95% Cr-I 0.16–2.08)). IPCs without daily drainage were less likely to effect a
definitive pleurodesis (enabling IPC removal) than talc slurry (OR for pleurodesis failure 7.60 (95% Cr-I
2.96–20.47)); however, pleurodesis efficacy may be increased by daily IPC drainage or administration of
talc slurry via the IPC.
There was insufficient comparable data to perform a NMA on post-intervention breathlessness outcomes;
however, additional data from newer RCTs did enable pairwise meta-analysis of post-intervention 100 mm
visual analogue dyspnoea scores. Data from two studies demonstrated that IPCs (without daily drainage)
provide equivalent breathlessness control when compared to talc slurry (mean difference −6.12 mm (95%
CI −16.32–4.08)).
Meta-analysis of data from three studies demonstrated that participants who received an IPC were less
likely to require a repeat invasive pleural procedure than those treated with talc slurry (OR 0.25 (95% CI
0.13–0.48)). The risk of repeat invasive intervention when treated with talc poudrage was similar to talc
slurry (OR 0.96 (95% CI 0.59–1.56)).
We used NMA to compare rates of procedure-related fever and pain, which were the most widely reported
adverse events. There was no statistical evidence for differences between commonly used interventions.
Full results are available in the Cochrane publication [3].
Our updated review is the largest systematic review and NMA to date of evidence for the management of
MPE, which attempts to combine all available randomised data on the wide variety of interventions. We
included six additional studies evaluating IPCs which, when combined with the two studies included in the
previous review, establish that IPCs provide an alternative first-line approach to MPE management.
Although associated with lower definitive pleurodesis rates, comparable breathlessness control can be
achieved, with a lower risk of requiring a repeat invasive pleural procedure compared to talc slurry. This
may be advantageous to individuals who wish to avoid an inpatient stay and to minimise future invasive
procedures. None of the included studies have quantified the overall healthcare utilisation of IPCs,
including community drainages, which is a consideration for future research.
We now highlight that since comparable breathlessness control can be achieved by commonly utilised
interventions, patient choice is likely to be a key determinant when selecting an intervention. This
emphasises the importance of informed discussion to facilitate joint decision making.
TABLE 1 Summary of findings for pleurodesis failure#
Relative effect,
network estimate
Relative effect¶ Anticipated absolute effect+ Interpretation of
findings§





18 failures per 100
participants (11–24)
Not estimable Not estimable Reference
comparator
Talc poudrage 0.50 (0.21–1.02) 0.78 (0.16–2.08) 18 failures per 100
participants (11–24)
10 failures per 100
participants (4–19)





Bleomycin 2.24 (1.10–4.68) 3.93 (1.10–16.94) 18 failures per 100
participants (11–24)
32 failures per 100
participants (17–52)






7.60 (2.96–20.47) 8.60 (2.26–30.15) 18 failures per 100
participants (11–24)
62 failures per 100
participants (36–82)




Doxycycline 2.51 (0.81–8.40) 1.89 (0.32–8.84) 18 failures per 100
participants (11–24)
35 failures per 100
participants (13–65)




Placebo 15.90 (3.76–79.90) 17.46 (3.33–97.26) 18 failures per 100
participants (11–24)
77 failures per 100
participants (42–95)




Data are presented as odds ratio (95% credible interval). IPC: indwelling pleural catheter. #: total studies in network meta-analysis (NMA): n=55,
total participants in NMA: n=3758, interventions in NMA: n=21; ¶: network estimate from sensitivity analysis of studies at low risk of bias, according
to the Cochrane risk of bias assessment criteria, these data are included within the summary of findings to reflect the ORs and credible intervals
from the network estimates in which we have the greatest level of certainty in the evidence; +: calculated using data from primary outcome network
of pleurodesis failure; §: based on GRADE outcome of certainty in the evidence.
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The diversity of outcome measurement scales used by studies which assessed patient-related quality of life
and symptom control precluded NMA of these outcomes. Although secondary outcomes of our review,
these are important considerations when selecting a management strategy. The development of MPE
specific, validated patient-reported outcome measurement tools would be hugely beneficial when
combining data from future RCTs to increase the applicability of evidence to everyday practice.
The risk of bias in the included RCTs was substantial; only three out of 80 were judged as low risk across
all seven domains of the Cochrane risk of bias tool. We added summary of findings tables to this updated
article and chose to include results from our sensitivity analysis of studies at low risk of bias (which we
defined as a maximum of one high-risk domain), to reflect the estimates in which we had the greatest level
of certainty. This produced a reduced heterogeneity estimate, indicating that bias may have contributed to
the heterogeneity observed in the primary NMA. Methodological differences between studies, including
definition of pleurodesis failure and time-point at which this was assessed, in addition to variation in drug
doses and effects of differing tumour subtypes, may also have contributed to the heterogeneity observed,
signifying the complexity of the MPE condition and its treatments.
Based on the available evidence, talc slurry and talc poudrage are effective methods for achieving a
pleurodesis. Whilst IPCs are less likely to effect a pleurodesis, they confer a lower risk of requiring repeat
invasive intervention. Breathlessness control is comparable for these commonly utilised interventions. It is
therefore essential that a range of treatment strategies are accessible to patients depending on their clinical
situation and that personal preferences are considered.
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